FOLD - Amicus Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

FOLD is currently covered by 10 analysts with an average price target of $11.33. This is a potential upside of $5.4 (91.06%) from yesterday's end of day stock price of $5.93.

Amicus Therapeutics's activity chart (see below) currently has 108 price targets and 94 ratings on display. The stock rating distribution of FOLD is 20.83% HOLD and 79.17% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 46.74% with an average time for these price targets to be met of 354.71 days.

Highest price target for FOLD is $21, Lowest price target is $9, average price target is $15.9.

Most recent stock forecast was given by SALVEEN RICHTER from GOLDMAN SACHS on 02-May-2025.

Currently out of the existing stock ratings of FOLD, 5 are a HOLD (20.83%), 19 are a BUY (79.17%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$9

$3.07 (51.77%)

$14

1 months 27 days ago
(02-May-2025)

4/6 (66.67%)

$2.33 (34.93%)

165

Buy

$21

$15.07 (254.13%)

$21

5 months 14 days ago
(15-Jan-2025)

0/7 (0%)

$11.73 (126.54%)

Buy

$12

$6.07 (102.36%)

$18

6 months 16 days ago
(13-Dec-2024)

0/4 (0%)

$2.64 (28.21%)

Buy

$17

$11.07 (186.68%)

$16

7 months 17 days ago
(12-Nov-2024)

6/15 (40%)

$6.51 (62.06%)

454

Buy

$15

$9.07 (152.95%)

$13

7 months 22 days ago
(07-Nov-2024)

2/4 (50%)

$4.02 (36.61%)

434

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is FOLD (Amicus Therapeutics) average time for price targets to be met?

On average it took 354.71 days on average for the stock forecasts to be realized with a an average price target met ratio 46.74

Which analyst has the current highest performing score on FOLD (Amicus Therapeutics) with a proven track record?

DEBJIT CHATTOPADHYAY

Which analyst has the most public recommendations on FOLD (Amicus Therapeutics)?

Debjit Chattopadhyay works at GUGGENHEIM and has 7 price targets and 3 ratings on FOLD

Which analyst is the currently most bullish on FOLD (Amicus Therapeutics)?

Michael Ulz with highest potential upside - $19.07

Which analyst is the currently most reserved on FOLD (Amicus Therapeutics)?

Gil Blum with lowest potential downside - -$0

Amicus Therapeutics in the News

FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls

Amicus Therapeutics FOLD reported first-quarter 2025 adjusted earnings of 3 cents per share, which missed the Zacks Consensus Estimate of 8 cents. The company had reported a loss of 2 cents per share in the year-ago quarter.(Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Revenues totaled $125.2 million, up 13% year over...

Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -62.50%. A quarter ago, it was expected that...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?